⌘K
Loading ticker…
Lexeo Therapeutics, Inc. Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, Lexeo Therapeutics, Inc. Common Stock (LXEO) has a 3-month relative strength percentile of 20 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 42. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 7.4%, relative volume 2.73×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
20 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
LXEO is in a stage 4 downtrend, week 2. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -9.9% / -33.5%.
Attention is elevated versus its own recent norm without the relative strength to match — the loud-but-lagging pattern. Worth a skeptical eye; not a short signal.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
LXEO is held by 5 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $13M notional. Top 3 carry $33M.
Top 5 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $13M |
| XBIState Street SPDR S&P Biotech ETF | 0.14% | $11M |
| IWMiShares Russell 2000 ETF | 0.01% | $9M |
| VXFVanguard Extended Market ETF | 0.00% | $4M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.00% | $507K |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | LXEO Jan avg: -5.04% median: -17.48% win: 33% σ: 28.65% n: 3 2023-11-06 → 2026-05-29 | LXEO Feb avg: -21.71% median: -14.70% win: 0% σ: 22.93% n: 3 2023-11-06 → 2026-05-29 | LXEO Mar avg: 2.84% median: 7.25% win: 67% σ: 21.04% n: 3 2023-11-06 → 2026-05-29 | LXEO Apr avg: -2.71% median: -0.78% win: 33% σ: 17.01% n: 3 2023-11-06 → 2026-05-29 | LXEO May avg: -2.32% median: -9.74% win: 33% σ: 32.82% n: 3 2023-11-06 → 2026-05-29 | LXEO Jun avg: 22.12% median: 22.12% win: 50% σ: 36.30% n: 2 2023-11-06 → 2026-05-29 (current) | LXEO Jul avg: -2.05% median: -2.05% win: 50% σ: 27.87% n: 2 2023-11-06 → 2026-05-29 | LXEO Aug avg: -3.51% median: -3.51% win: 50% σ: 6.76% n: 2 2023-11-06 → 2026-05-29 | LXEO Sep avg: 8.58% median: 8.58% win: 50% σ: 42.48% n: 2 2023-11-06 → 2026-05-29 | LXEO Oct avg: 19.07% median: 19.07% win: 50% σ: 44.80% n: 2 2023-11-06 → 2026-05-29 | LXEO Nov avg: 9.75% median: 4.18% win: 67% σ: 14.84% n: 3 2023-11-06 → 2026-05-29 | LXEO Dec avg: -4.61% median: 0.71% win: 67% σ: 13.58% n: 3 2023-11-06 → 2026-05-29 |